{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:49:15Z","timestamp":1790617755518,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Targeted radioligand therapy of metastatic castration-resistant prostate cancer (mCRPC) with <jats:sup>177<\/jats:sup>Lu-PSMA (RLT) requires sufficient dose monitoring of the kidneys. Currently, dosimetry using SPECT\/CT-imaging is the most preferred method. However, SPECT\/CT is a time-consuming procedure and comprises additional radiation exposure to the patient. Moreover, not every therapeutic nuclear medicine facility has access to SPECT\/CT. Therefore, the aim of this study was to develop a new procedure of kidney dosimetry without the use of SPECT\/CT and evaluate this method in a large cohort of patients with mCRPC undergoing RLT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Procedures<\/jats:title>\n            <jats:p>A dedicated torso phantom with kidneys filled with a solution of <jats:sup>177<\/jats:sup>Lu-PSMA was used for quantitative calibration of a SPECT-camera. The calculated sensitivity was adapted according to the individual attenuation of the patient in four directions from the kidney surface to the body surface (ventral, dorsal, left and right) obtained from a previously performed CT. A total of 196 patients undergoing 926 cycles of <jats:sup>177<\/jats:sup>Lu-PSMA therapy were retrospectively analyzed. Abdominal SPECT was performed 24, 48 and 72\u00a0h after administration of <jats:sup>177<\/jats:sup>Lu-PSMA including scatter and dead-time correction in every patient. Kidney dose was calculated using an individual attenuation-based procedure and compared to values from international literature.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Volumes of interest of the kidneys were drawn in the three sequential SPECT-images to calculate intra-renal effective half-life. Absolute quantification of activity in the kidneys was accomplished obtaining a patient individual sensitivity based on the individual attenuation in the patient. Kidney dose was then calculated applying a bi-exponential time activity curve in Microsoft EXCEL. Mean kidney dose per administered activity was 0.54\u00a0(\u00b1\u20090.26)\u00a0Gy\/GBq.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>With the presented procedure a reliable kidney dosimetry is possible without the use of SPECT\/CT. Facilities without SPECT\/CT are therefore able to perform an adequate kidney dosimetry without additional radiation exposure for the patient.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11307-025-01998-2","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T04:49:15Z","timestamp":1742532555000},"page":"400-409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry in 177Lu-PSMA-617 Radioligand Therapy"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-1452","authenticated-orcid":false,"given":"Christian","family":"Happel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"V\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bockisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Groener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Leonh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Sabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"2","key":"1998_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00259-016-3548-5","volume":"44","author":"VR McCready","year":"2017","unstructured":"McCready VR (2017) Radioiodine \u2013 the success story of Nuclear Medicine: 75th Anniversary of the first use of Iodine-131 in humans. Eur J Nucl Med Mol Imaging 44(2):179\u2013182","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1998_CR2","doi-asserted-by":"publisher","first-page":"13925","DOI":"10.1038\/s41598-022-18170-3","volume":"12","author":"C Happel","year":"2022","unstructured":"Happel C, Kranert WT, Bockisch B et al (2022) The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodules. Sci Rep 12(1):13925","journal-title":"Sci Rep"},{"issue":"1","key":"1998_CR3","doi-asserted-by":"publisher","first-page":"21190","DOI":"10.1038\/s41598-023-47228-z","volume":"13","author":"C Happel","year":"2023","unstructured":"Happel C, Bockisch B, Leonh\u00e4user B et al (2023) The influence of thionamides on intra-thyroidal uptake of 131I during radioiodine-131 treatment of Graves\u2019 disease. Sci Rep 13(1):21190","journal-title":"Sci Rep"},{"issue":"6","key":"1998_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1055\/a-1035-9052","volume":"58","author":"K Michalski","year":"2019","unstructured":"Michalski K, Mix M, Meyer PT et al (2019) Determination of whole-body tumour burden on [68Ga]PSMA-11 PET\/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: A retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy. Nuklearmedizin 58(6):443\u2013450","journal-title":"Nuklearmedizin"},{"issue":"2","key":"1998_CR5","first-page":"74","volume":"7","author":"A Sabet","year":"2017","unstructured":"Sabet A, Haug AR, Eiden C et al (2017) Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. Am J Nucl Med Mol Imaging 7(2):74\u201383","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"5","key":"1998_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/a-0987-9689","volume":"58","author":"B Leonh\u00e4user","year":"2019","unstructured":"Leonh\u00e4user B, Happel C, Gr\u00f6ner D et al (2019) Evaluation of intratherapeutic 177Lu-HA-DOTATATE treatment in neuroendocrine tumors: Dosimetry with SPECT, whole-body imaging and gamma probe. Nuklearmedizin 58(5):379\u2013386","journal-title":"Nuklearmedizin"},{"issue":"16","key":"1998_CR7","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.3390\/cancers13164017","volume":"13","author":"D Groener","year":"2021","unstructured":"Groener D, Baumgarten J, Haefele S et al (2021) Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement. Cancers (Basel) 13(16):4017","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1998_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","volume":"11","author":"D Groener","year":"2021","unstructured":"Groener D, Nguyen CT, Baumgarten J et al (2021) Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res 11(1):61","journal-title":"EJNMMI Res"},{"issue":"15","key":"1998_CR9","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.3390\/cancers15153878","volume":"15","author":"D Groener","year":"2023","unstructured":"Groener D, Wichert J, Adams M et al (2023) Impact of [177Lu]Lu-PSMA-617 radioligand therapy on reference organ uptake assessed by [68Ga]Ga-PSMA-11-PET\/CT. Cancers (Basel) 15(15):3878","journal-title":"Cancers (Basel)"},{"key":"1998_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/cancers14030557","volume":"14","author":"J Baumgarten","year":"2022","unstructured":"Baumgarten J, Groener D, Nguyen Ngoc C et al (2022) Safety and efficacy of 177Lutetium-PSMA-617 radioligand therapy shortly after failing 223Radium-Dichloride. Cancers (Basel) 14:557","journal-title":"Cancers (Basel)"},{"key":"1998_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07006-z","author":"MB Bastian","year":"2024","unstructured":"Bastian MB, Sieben M, Blickle A et al (2024) Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-024-07006-z. Online ahead of print","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1998_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3413\/Nukmed-0925-17-08","volume":"56","author":"H H\u00e4nscheid","year":"2017","unstructured":"H\u00e4nscheid H, Lapa C, Buck AK et al (2017) Absorbed dose estimates from a single measurement one to three days after the administration of 177Lu-DOTATATE\/-TOC. Nuklearmedizin 56(6):219\u2013224","journal-title":"Nuklearmedizin"},{"issue":"9","key":"1998_CR13","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M et al (2023) Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 50(9):2830\u20132845","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1998_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.zemedi.2011.05.001","volume":"21","author":"J Fitschen","year":"2011","unstructured":"Fitschen J, Knoop BO, Behrendt R et al (2011) External radiation exposure and effective half-life in Lu-177-Dota-Tate therapy. Z Med Phys 21(4):266\u2013273","journal-title":"Z Med Phys"},{"issue":"12","key":"1998_CR15","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Fendler WP, Eiber M et al (2019) EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 46(12):2536\u20132544","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1998_CR16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/a-1697-8126","volume":"61","author":"WT Kranert","year":"2022","unstructured":"Kranert WT, Bockisch B, Wichert J et al (2022) Anticipating criteria for discharge after Lu-177-PSMA treatment - discussion of several scenarios. Nuklearmedizin 61(2):111\u2013119","journal-title":"Nuklearmedizin"},{"issue":"7","key":"1998_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/RLU.0000000000002102","volume":"43","author":"A Khawar","year":"2018","unstructured":"Khawar A, Eppard E, Sinnes JP et al (2018) Prediction of normal organ absorbed doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 pharmacokinetics in patients with metastatic castration resistant prostate carcinoma. Clin Nucl Med 43(7):486\u2013491","journal-title":"Clin Nucl Med"},{"issue":"2","key":"1998_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(2):197\u2013209","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1998_CR19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3413\/Nukmed-2018030003","volume":"57","author":"J Kotzerke","year":"2018","unstructured":"Kotzerke J, B\u00f6hmer D, Schlomm T et al (2018) PSMA-PET\/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection. Nuklearmedizin 57(3):69\u201373","journal-title":"Nuklearmedizin"},{"issue":"6","key":"1998_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2967\/jnumed.115.156133","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Bluemel C, Weineisen M et al (2015) Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56(6):855\u2013861","journal-title":"J Nucl Med"},{"key":"1998_CR21","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.2147\/OTT.S140671","volume":"10","author":"A Yordanova","year":"2017","unstructured":"Yordanova A, Eppard E, K\u00fcrpig S et al (2017) Theranostics in nuclear medicine practice. Onco Targets Ther 10:4821\u20134828","journal-title":"Onco Targets Ther"},{"issue":"1091","key":"1998_CR22","doi-asserted-by":"publisher","first-page":"20180440","DOI":"10.1259\/bjr.20180440","volume":"91","author":"JH Turner","year":"2018","unstructured":"Turner JH (2018) An introduction to the clinical practice of theranostics in oncology. Br J Radiol 91(1091):20180440","journal-title":"Br J Radiol"},{"issue":"12","key":"1998_CR23","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.1002\/mp.13846","volume":"46","author":"A Rinscheid","year":"2019","unstructured":"Rinscheid A, Kletting P, Eiber M et al (2019) Technical note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar\/SPECT method in 177Lu-PSMA therapy. Med Phys 46(12):5861\u20135866","journal-title":"Med Phys"},{"issue":"7","key":"1998_CR24","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C et al (2016) 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy. J Nucl Med 57(7):1006\u20131013","journal-title":"J Nucl Med"},{"issue":"4","key":"1998_CR25","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","volume":"50","author":"P Mhawech-Fauceglia","year":"2007","unstructured":"Mhawech-Fauceglia P, Zhang S, Terracciano L et al (2007) Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 50(4):472\u2013483","journal-title":"Histopathology"},{"issue":"1","key":"1998_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C et al (2016) Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 43(1):42\u201351","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1998_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00120-016-0274-3","volume":"56","author":"MM Heck","year":"2017","unstructured":"Heck MM, Retz M, Tauber R et al (2017) PSMA-targeted radioligand therapy in prostate cancer. Urologe A 56(1):32\u201339","journal-title":"Urologe A"},{"issue":"9","key":"1998_CR28","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00259-017-3681-9","volume":"44","author":"A Yordanova","year":"2017","unstructured":"Yordanova A, Becker A, Eppard E et al (2017) The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging 44(9):1473\u20131479","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1998_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005583","author":"MB Bastian","year":"2024","unstructured":"Bastian MB, Sieben M, Burgard C et al (2024) Outcome and renal safety of PSMA-targeted radioligand therapy in mCRPC patients with preexisting impaired renal function. Clin Nucl Med. https:\/\/doi.org\/10.1097\/RLU.0000000000005583. Online ahead of print","journal-title":"Clin Nucl Med"},{"issue":"13","key":"1998_CR30","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","volume":"45","author":"M Cremonesi","year":"2018","unstructured":"Cremonesi M, Ferrari ME, Bodei L et al (2018) Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging 45(13):2426\u20132441","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1998_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.zemedi.2016.02.002","volume":"27","author":"D Thorwarth","year":"2017","unstructured":"Thorwarth D, Notohamiprodjo M, Zips D et al (2017) Personalized precision radiotherapy by integration of multi-parametric functional and biological imaging in prostate cancer: A feasibility study. Z Med Phys 27(1):21\u201330","journal-title":"Z Med Phys"},{"issue":"2","key":"1998_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.zemedi.2019.10.005","volume":"30","author":"TI G\u00f6tz","year":"2020","unstructured":"G\u00f6tz TI, Lang EW, Schmidkonz C et al (2020) Particle filter de-noising of voxel-specific time-activity-curves in personalized 177Lu therapy. Z Med Phys 30(2):116\u2013134","journal-title":"Z Med Phys"},{"issue":"8","key":"1998_CR33","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt C, Zhang J, Kulkarni HR et al (2022) Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med 63(8):1199\u20131207","journal-title":"J Nucl Med"},{"issue":"3","key":"1998_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00259-019-04583-2","volume":"47","author":"J Maffey-Steffan","year":"2020","unstructured":"Maffey-Steffan J, Scarpa L, Svirydenka A et al (2020) The 68Ga\/177Lu-theragnostic concept in PSMA-targeting of metastatic castration\u2013resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur J Nucl Med Mol Imaging 47(3):695\u2013712","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1998_CR35","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","volume":"61","author":"PA Jackson","year":"2019","unstructured":"Jackson PA, Hofman MS, Hicks RJ et al (2019) Radiation dosimetry in 177Lu-PSMA-617 therapy using a single post-treatment SPECT\/CT: a novel methodology to generate time- and tissue-specific dose factors. J Nucl Med 61(7):1030\u20131036","journal-title":"J Nucl Med"},{"issue":"3","key":"1998_CR36","first-page":"292","volume":"36","author":"Kamaldeep","year":"2020","unstructured":"Kamaldeep, Wanage G, Sahu SK et al (2020) Examining absorbed doses of indigenously developed 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients at baseline and during course of peptide receptor radioligand therapy. Cancer Biother Radiopharm 36(3):292\u2013304","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"1998_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/RLU.0000000000002942","volume":"45","author":"A \u00d6zkan","year":"2020","unstructured":"\u00d6zkan A, U\u00e7ar B, Seymen H et al (2020) Posttherapeutic critical organ dosimetry of extensive 177Lu-PSMA inhibitor therapy with metastatic castration-resistant prostate cancer: one center results. Clin Nucl Med 45(4):288\u2013291","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1998_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MNM.0000000000000606","volume":"38","author":"MP Yadav","year":"2017","unstructured":"Yadav MP, Ballal S, Tripathi M et al (2017) Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Nucl Med Commun 38(1):91\u201398","journal-title":"Nucl Med Commun"},{"issue":"8","key":"1998_CR39","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M et al (2016) PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617. J Nucl Med 57(8):1170\u20131176","journal-title":"J Nucl Med"},{"issue":"1","key":"1998_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40658-021-00385-4","volume":"8","author":"F Rosar","year":"2021","unstructured":"Rosar F, Sch\u00f6n N, Bohnenberger H et al (2021) Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy. EJNMMI Phys 8(1):40","journal-title":"EJNMMI Phys"},{"key":"1998_CR41","first-page":"1","volume":"158","author":"ML Belli","year":"2020","unstructured":"Belli ML, Mezzenga E, Di Iorio V et al (2020) A whole body dosimetry protocol for peptide-receptor radionuclide therapy (Prrt): 2d planar image and hybrid 2d+3d SPECT\/CT image methods. J Vis Exp 158:1\u201310","journal-title":"J Vis Exp"},{"key":"1998_CR42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/B978-1-4832-3110-5.50011-X","volume":"4","author":"WE Siri","year":"1956","unstructured":"Siri WE (1956) The gross composition of the body. Adv Biol Med Phys 4:239\u2013280","journal-title":"Adv Biol Med Phys"},{"key":"1998_CR43","unstructured":"Eckerman KF, Endo A (2009) MIRD radionuclide data and decay\u00a0schemes. SNM Advancing Molecular Imaging and Therapy. Society of Nuclear Medicine, Reston, VA"},{"issue":"4","key":"1998_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00259-010-1685-9","volume":"38","author":"E Vegt","year":"2011","unstructured":"Vegt E, Melis M, Eek A et al (2011) Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging 38(4):623\u2013632","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1998_CR45","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s00259-009-1282-y","volume":"37","author":"EJ Rolleman","year":"2010","unstructured":"Rolleman EJ, Melis M, Valkema R et al (2010) Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 37(5):1018\u20131031","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1998_CR46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2967\/jnumed.114.147181","volume":"56","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Giesel FL, Leotta K et al (2015) PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med 56(2):293\u2013298","journal-title":"J Nucl Med"},{"key":"1998_CR47","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00259-023-06119-1","volume":"50","author":"N Mader","year":"2023","unstructured":"Mader N, Nguyen Ngoc C, Kirkg\u00f6ze B et al (2023) Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 50:1811\u20131821","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1998_CR48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J et al (2019) Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med 60(4):517\u2013523","journal-title":"J Nucl Med"},{"issue":"3","key":"1998_CR49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/molecules24030621","volume":"24","author":"A Sarnelli","year":"2019","unstructured":"Sarnelli A, Belli ML, Di Iorio V et al (2019) Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: Preliminary results of EUDRACT\/RSO 2016\u2013002732-32 IRST protocol. Molecules 24(3):621","journal-title":"Molecules"},{"issue":"1","key":"1998_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13550-019-0548-z","volume":"9","author":"A Gosewisch","year":"2019","unstructured":"Gosewisch A, Ilhan H, Tattenberg S et al (2019) 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT\/CT. EJNMMI Res 9(1):76","journal-title":"EJNMMI Res"},{"issue":"3","key":"1998_CR51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11307-016-0942-0","volume":"18","author":"M Hohberg","year":"2016","unstructured":"Hohberg M, Eschner W, Schmidt M et al (2016) Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [(177)Lu]DKFZ-PSMA-617. Mol Imaging Biol 18(3):437\u2013445","journal-title":"Mol Imaging Biol"},{"key":"1998_CR52","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1109\/TNS.1978.4329385","volume":"1","author":"LT Chang","year":"1978","unstructured":"Chang LT (1978) A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1:638\u2013643","journal-title":"IEEE Trans Nucl Sci"},{"key":"1998_CR53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0032-1325873","volume":"05","author":"Z Siljic","year":"2012","unstructured":"Siljic Z (2012) Basal ganglia diagnostics: low-dose CT-attenuation correction vs. Chang correction. Radiopraxis 05:229\u2013245","journal-title":"Radiopraxis"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-01998-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-01998-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-01998-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:02:14Z","timestamp":1749754934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-01998-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1998"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-01998-2","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Informed consent Informed consent was obtained from all individual participants included in the study. The study was approved by the local ethic committee (ethic committee of the Goethe University Frankfurt; approval number: 310\/18).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}